Sugi Predict
/ Targets
/ NEK1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to NEK1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus |
PHASE3 | UNKNOWN |
| Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy |
PHASE2 | COMPLETED |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... |
PHASE2 | COMPLETED |
| A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas |
PHASE2 | SUSPENDED |
| A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia |
PHASE2 | WITHDRAWN |
| Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers |
PHASE1/PHASE2 | RECRUITING |
| Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations |
PHASE2 | COMPLETED |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer |
PHASE2 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b |
PHASE1 | COMPLETED |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy |
PHASE1 | RECRUITING |
| Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers |
PHASE1 | COMPLETED |
| Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel |
PHASE1 | COMPLETED |
| Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy |
PHASE1 | COMPLETED |
| PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck |
PHASE1 | COMPLETED |
| A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 |
PHASE1 | COMPLETED |
| Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer |
PHASE1 | COMPLETED |
| Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 |
EARLY_PHASE1 | COMPLETED |
| The Roles of Neutrophil Elastase in Lung Cancer |
nan | UNKNOWN |
| Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients |
nan | RECRUITING |
| Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus |
nan | COMPLETED |
| NTRK 1,2,3 Rearrangements in Patients With Solid Tumors |
nan | ACTIVE_NOT_RECRUITING |
| p-AKT Expression on Clinical Outcomes in Malignant Lymphoma |
nan | COMPLETED |
| Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children |
nan | COMPLETED |
| Molecular Phenotype Changes and Personalized Treatment for CRPC |
nan | UNKNOWN |
| Muscle Wasting in Cancer (MWIC) |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a NEK1 binder may also engage these)